The FDA has ordered a recall of specific batches of generic metformin from three manufacturers after testing revealed NDMA levels exceeding acceptable daily intake limits by up to 10 times.

Affected Batches

The recall covers metformin hydrochloride extended-release tablets from Amneal, Apotex, and Lupin Pharmaceuticals. The contamination was discovered during routine FDA testing of generic drug quality.

Patient Guidance

Patients should not stop taking metformin without consulting their doctor, as the risk of uncontrolled diabetes outweighs the cancer risk from short-term exposure. Alternative batches are available.